PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Where’s your place in the CMO hierarchy?
Find out in the CMO industry’s authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance over time, and CMOs to benchmark their performance against the industry.
Our research team crunched the numbers on 2016 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. For the first time, we are including information on the location of outsourced dose manufacturing facilities.
PharmSource’s data-rich Trend Report, CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition, concludes that 2016 was not a halcyon year for new drug approvals with only 25 NMEs approved since 2010.
Scope
NA
Reasons to Buy
This report is required reading for:
CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.